- Home
- ATER vs CANF Comparison
ATER vs CANF Comparison
Compare ATER & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATER
- CANF
- Stock Information
- Founded
- ATER 2014
- CANF 1994
- Country
- ATER United States
- CANF Israel
- Employees
- ATER N/A
- CANF N/A
- Industry
- ATER Home Furnishings
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ATER Consumer Discretionary
- CANF Health Care
- Exchange
- ATER Nasdaq
- CANF Nasdaq
- Market Cap
- ATER 10.3M
- CANF 9.6M
- IPO Year
- ATER N/A
- CANF N/A
- Fundamental
- Price
- ATER $1.07
- CANF $0.53
- Analyst Decision
- ATER
- CANF Strong Buy
- Analyst Count
- ATER 0
- CANF 2
- Target Price
- ATER N/A
- CANF $14.50
- AVG Volume (30 Days)
- ATER 130.3K
- CANF 249.7K
- Earning Date
- ATER 11-10-2025
- CANF 11-27-2025
- Dividend Yield
- ATER N/A
- CANF N/A
- EPS Growth
- ATER N/A
- CANF N/A
- EPS
- ATER N/A
- CANF N/A
- Revenue
- ATER $85,668,000.00
- CANF $560,000.00
- Revenue This Year
- ATER N/A
- CANF $461.72
- Revenue Next Year
- ATER $7.48
- CANF N/A
- P/E Ratio
- ATER N/A
- CANF N/A
- Revenue Growth
- ATER N/A
- CANF N/A
- 52 Week Low
- ATER $0.90
- CANF $0.47
- 52 Week High
- ATER $3.50
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- ATER 48.70
- CANF 32.57
- Support Level
- ATER $1.04
- CANF $0.47
- Resistance Level
- ATER $1.12
- CANF $0.60
- Average True Range (ATR)
- ATER 0.08
- CANF 0.03
- MACD
- ATER -0.00
- CANF -0.01
- Stochastic Oscillator
- ATER 20.00
- CANF 32.63
About ATER Aterian Inc.
Aterian Inc is a technology-enabled consumer products company. Its product categories include home and kitchen appliances, kitchenware, environmental appliances (dehumidifiers and air conditioners), beauty-related products and, consumer electronics. It has various owned and operates brands, including HomeLabs, Squatty Potty, Healing Solutions, PurSteam, and others. The company generates revenue through the online sales of various consumer products that are sold online.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).